Benjamin Burnett
Stock Analyst at Wells Fargo
(2.45)
# 2,500
Out of 5,050 analysts
78
Total ratings
51.79%
Success rate
-0.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Overweight | $163 → $157 | $135.01 | +16.29% | 2 | Nov 4, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $44 → $42 | $32.10 | +30.84% | 2 | Oct 29, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $31 | $22.28 | +39.14% | 1 | Sep 3, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Equal-Weight | $16 | $18.71 | -14.48% | 1 | Sep 3, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.05 | +185.71% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $53.51 | -8.43% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $86.28 | +41.40% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $21.89 | +215.21% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $29.61 | +129.65% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.12 | +310.71% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $11.61 | +395.48% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $6.19 | +12,495.68% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $70.55 | +31.82% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $44 | $37.81 | +16.37% | 2 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $444.74 | -4.89% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $60.40 | +5.96% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $83.64 | +12.39% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $1.72 | +132.56% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.70 | +170.64% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.18 | +1,046.79% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $56.03 | +542.51% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.47 | +3,304.98% | 1 | Jan 6, 2021 |
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $163 → $157
Current: $135.01
Upside: +16.29%
Alkermes
Oct 29, 2025
Maintains: Overweight
Price Target: $44 → $42
Current: $32.10
Upside: +30.84%
Centessa Pharmaceuticals
Sep 3, 2025
Initiates: Overweight
Price Target: $31
Current: $22.28
Upside: +39.14%
Avadel Pharmaceuticals
Sep 3, 2025
Initiates: Equal-Weight
Price Target: $16
Current: $18.71
Upside: -14.48%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.05
Upside: +185.71%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $53.51
Upside: -8.43%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $86.28
Upside: +41.40%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $21.89
Upside: +215.21%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $29.61
Upside: +129.65%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.12
Upside: +310.71%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $11.61
Upside: +395.48%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $6.19
Upside: +12,495.68%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $70.55
Upside: +31.82%
Nov 4, 2025
Maintains: Overweight
Price Target: $48 → $44
Current: $37.81
Upside: +16.37%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $444.74
Upside: -4.89%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $60.40
Upside: +5.96%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $83.64
Upside: +12.39%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $1.72
Upside: +132.56%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.70
Upside: +170.64%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.18
Upside: +1,046.79%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $56.03
Upside: +542.51%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.47
Upside: +3,304.98%